3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Non-Small-Cell Lung
42
Lung Neoplasms
18
Melanoma
14
Carcinoma, Hepatocellular
14
Neoplasm Metastasis
13
Esophageal Neoplasms
11
Squamous Cell Carcinoma of Head and Neck
9
Breast Neoplasms
8
Head and Neck Neoplasms
6
Esophageal Squamous Cell Carcinoma
6
Rectal Neoplasms
5
Colorectal Neoplasms
5
Stomach Neoplasms
4
Recurrence
4
Neoplasms
4
Carcinoma, Renal Cell
4
Brain Neoplasms
4
Uterine Cervical Neoplasms
3
Triple Negative Breast Neoplasms
3
Small Cell Lung Carcinoma
3
Sarcoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Pancreatic Neoplasms
3
Multiple Myeloma
3
Cholangiocarcinoma
3
Carcinoma, Transitional Cell
3
Radiation Pneumonitis
2
Pathologic Complete Response
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Oropharyngeal Neoplasms
2
Interventions
Ipilimumab
6
tremelimumab
5
durvalumab
5
Nivolumab
3
Capecitabine
3
Radiotherapy
2
Radiation
2
Paclitaxel
2
CTLA-4 Antigen
2
Blood Specimen Collection
2
relatlimab
1
poly ICLC
1
lenvatinib
1
folfirinox
1
balstilimab
1
Vaccines
1
Vaccination
1
Surgical Procedures, Operative
1
Radiosurgery
1
Platinum
1
Peptides
1
Pemetrexed
1
Oxaliplatin
1
Opdualag
1
Monophenol Monooxygenase
1
Melphalan
1
Leucovorin
1
Immunotherapy
1
Fluorouracil
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Diabetes Mellitus, Insulin-Dependent, 12
×
Immunotherapy
×
Clear all
NCT03116529
2024-11-04
NEXIS
University of Maryland, Baltimore
Phase 1/2
Terminated
22 enrolled